| Authors: |
Dijkgraaf FE; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Matos TR; Department of Dermatology and Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands., Hoogenboezem M; Research Facility, Sanquin Amsterdam, Amsterdam, the Netherlands., Toebes M; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Vredevoogd DW; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mertz M; BioImaging Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van den Broek B; BioImaging Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Song JY; Animal Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Teunissen MBM; Department of Dermatology and Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands., Luiten RM; Department of Dermatology and Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands., Beltman JB; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands., Schumacher TN; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. t.schumacher@nki.nl. |
